0K9E Stock Overview
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Novartis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF92.79 |
| 52 Week High | CHF111.82 |
| 52 Week Low | CHF92.05 |
| Beta | 0.47 |
| 1 Month Change | -3.70% |
| 3 Month Change | -14.11% |
| 1 Year Change | -5.85% |
| 3 Year Change | 5.39% |
| 5 Year Change | 22.33% |
| Change since IPO | -1.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K9E | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.1% | 0.2% | -1.4% |
| 1Y | -5.8% | -5.3% | -2.4% |
Return vs Industry: 0K9E matched the UK Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: 0K9E underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| 0K9E volatility | |
|---|---|
| 0K9E Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0K9E has not had significant price volatility in the past 3 months.
Volatility Over Time: 0K9E's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 76,057 | Vas Narasimhan | www.novartis.com |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG Fundamentals Summary
| 0K9E fundamental statistics | |
|---|---|
| Market cap | US$202.85b |
| Earnings (TTM) | US$8.57b |
| Revenue (TTM) | US$46.66b |
23.7x
P/E Ratio4.3x
P/S RatioIs 0K9E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K9E income statement (TTM) | |
|---|---|
| Revenue | US$46.66b |
| Cost of Revenue | US$12.02b |
| Gross Profit | US$34.64b |
| Other Expenses | US$26.07b |
| Earnings | US$8.57b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 23, 2024
| Earnings per share (EPS) | 3.91 |
| Gross Margin | 74.24% |
| Net Profit Margin | 18.36% |
| Debt/Equity Ratio | 52.6% |
How did 0K9E perform over the long term?
See historical performance and comparison